SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer.

SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates. Our lead pipeline programs are in potentially registrational clinical trials for rare oncology indications. Nirogacestat, our gamma secretase inhibitor, is in a Phase 3 clinical trial (the DeFi trial) for the treatment of desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors. There are currently no approved therapies for patients with desmoid tumors. Mirdametinib, our MEK inhibitor, is in a Phase 2b clinical trial (the ReNeu trial) for the treatment of adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), which are peripheral nerve sheath tumors that cause that result in severe pain, disfigurement and a shortened life span. SpringWorks is also advancing, in collaboration with industry leaders, several other programs addressing highly prevalent, genetically defined cancers, including evaluating nirogacestat as a cornerstone of BCMA combination therapy for patients with multiple myeloma and several efforts in RAS– and RAF-mutated solid tumors with next-generation precision medicine approaches for these cancer types.

SpringWorks is actively pursuing new licensing and partnership opportunities with industry leaders. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients.

We are led by an experienced management team with deep expertise in drug development and commercialization. Our team of SpringWorkers is focused on exceptional execution and is driven to deliver life-changing medicines for the patients who are counting on us. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients.